Clinical Trial

Effects of EPA Supplementation on Patients With Unresectable Hepatocellular Carcinoma.

Name: Effects of EPA Supplementation on Patients With Unresectable Hepatocellular Carcinoma. — clinical trial record (NCT07664007)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed

View on ClinicalTrials.gov →

Summary

Dietary intervention with eicosapentaenoic acid combined with chemotherapy may shift inflammatory mediators toward resolution in non-resectable hepatocarcinoma and help to preserve muscle mass.

Trial Details

NCT Number	NCT07664007
Lead Sponsor	Instituto de Investigación Sanitaria Aragón Collaborators: Hospital Clínico Universitario Lozano Blesa, Solutex GC S.L.
Conditions	Hepatocellular Carcinoma
Enrollment	18 participants
Start Date	2019-03-04
Primary Completion	2023-09-17 (estimated)
Study Completion	2025-06-20 (estimated)
Updated on ClinicalTrials.gov	2026-06-23